Teleflex posts strong Q3 earnings, but cuts EPS view for UroLift

Trending News 🌧️

Teleflex Inc ($NYSE:TFX)orporated is a global provider of medical technologies designed to improve the health and quality of people’s lives. They develop and manufacture products in the areas of critical care, anesthesia, urology, vascular access, and general surgery. Teleflex’s third quarter earnings topped estimates, however their adjusted EPS guidance was cut. For UroLift, Teleflex currently estimates 2022 revenues to be roughly $320 million, down from their previous guidance of $335 million.

Despite the EPS cut, Teleflex’s strong Q3 results show that the company is still performing well overall. Their products are in high demand and they continue to innovate in the medical field.

Earnings

The company posted strong earnings, but cut its EPS guidance for the UroLift system. In the quarter ended September 30, Teleflex Inc. earned 2795.0 million in total revenue, up from 2537.2 million in the same quarter last year. The company attributed the decline in net income to lower sales of the UroLift system, which was offset by higher sales of other products.

Stock Price

So far, media coverage of the company has been mostly negative. On Tuesday, Teleflex’s stock opened at $216.0 and closed at $219.2, up by 2.2% from the previous closing price of 214.6.

VI Analysis

In general, a company’s fundamentals reflect its long-term potential. This is why VI app’s analysis of TELEFLEX INC‘s fundamentals is so important. The company is classified as a ‘rhino’ a type of company that has achieved moderate revenue or earnings growth. This means that it may be of interest to investors who are looking for companies that are stable and have a history of consistent growth. TELEFLEX INC has a high health score of 8/10, considering its cashflows and debt. This means that the company is capable of sustaining future operations in times of crisis.

However, the company is weak in terms of asset growth. Despite this, the company is strong in dividend and profitability.

VI Peers

Teleflex Inc., a leading global provider of medical technologies, offers a broad range of products and services for use in critical care and surgery. The company’s products are used by hospitals and other healthcare facilities worldwide. Teleflex’s competitors include Delta Asia International Corp, Meihua International Medical Technologies Co Ltd, and Shanghai Sanyou Medical Co Ltd.

– Delta Asia International Corp ($TPEX:6762)

Daiwa-Asia International Corp is a leading provider of financial services in Asia. The company offers a wide range of products and services, including banking, insurance, asset management, and securities brokerage. Daiwa-Asia has a strong presence in the region, with operations in Hong Kong, Singapore, Taiwan, China, and Japan. The company is listed on the Tokyo Stock Exchange and has a market capitalization of 5.54 billion as of 2022. Daiwa-Asia reported a return on equity of 11.54% for the year ended March 31, 2022.

– Meihua International Medical Technologies Co Ltd ($NASDAQ:MHUA)

Meihua International Medical Technologies Co Ltd is a Chinese medical technology company. It has a market cap of 191.52M as of 2022 and a Return on Equity of 16.31%. The company develops, manufactures, and sells medical devices and equipment. Its products include stents, catheters, and other cardiovascular products.

– Shanghai Sanyou Medical Co Ltd ($SHSE:688085)

Shanghai Sanyou Medical Co Ltd is a medical company with a market cap of 7.06B as of 2022 and a Return on Equity of 8.19%. The company specializes in the manufacture and sale of medical equipment and supplies. It is headquartered in Shanghai, China.

Summary

Teleflex Incorporated is a diversified global medical technology company that develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgery. Teleflex products are found in nearly every hospital worldwide. The company has three main business segments: critical care, surgical and cardiac care. Teleflex’s critical care products include catheters, tubing and other devices used in the intensive care unit.

The company’s surgical products are used in a variety of procedures, including gastrointestinal, urological, gynecological and general surgery. Teleflex’s cardiac care products are used in procedures to treat heart disease.